Treatment Guides

ALS Treatment in China: Medicines, Breathing Support, and Everyday Care

Amyotrophic lateral sclerosis, or ALS, affects the motor neurons that control voluntary movement. It can progressively impair limb strength, speech, swallowing, and the muscles used for breathing. The initial pattern and subsequent rate of change differ between individuals, so a useful treatment plan begins with the person's current function and needs rather than an assumed timetable.

Key takeaways

These excerpts come from the original article. Read the full sections below for context.

  • ALS diagnosis remains fundamentally clinical. Specialists look for progressive motor impairment, appropriate neurological findings, and supporting investigations while excluding other disease processes. Electromyography can reveal evidence of motor neuron dysfunction, but an abnormal result does not independently establish ALS outside the clinical context. Muscle twitching or weakness has several possible explanations and is not itself a diagnosis.
  • Respiratory muscle weakness may first appear as discomfort lying flat, disrupted sleep, morning headache, daytime sleepiness, or a weak cough. It does not always begin with an obvious episode of breathlessness. Assessment combines symptoms with respiratory function and, when needed, evaluation of sleep or gas exchange. A fingertip oxygen reading alone cannot establish whether ventilation is adequate.
  • List what the visit is intended to resolve: diagnostic review, interpretation of a genetic finding, drug assessment, ventilation adjustment, or help with swallowing and communication. Send the relevant records, including electrophysiology, imaging, genetics, weight and respiratory trends, current medicines, and equipment use. The proposed hospital can then explain which services it can provide and what information remains necessary.

Quick answer

Amyotrophic lateral sclerosis, or ALS, affects the motor neurons that control voluntary movement. It can progressively impair limb strength, speech, swallowing, and the muscles used for breathing. The initial pattern and subsequent rate of change differ between individuals, so a useful treatment plan begins with the person's current function and needs rather than an assumed timetable.

Full guide

Amyotrophic lateral sclerosis, or ALS, affects the motor neurons that control voluntary movement. It can progressively impair limb strength, speech, swallowing, and the muscles used for breathing. The initial pattern and subsequent rate of change differ between individuals, so a useful treatment plan begins with the person's current function and needs rather than an assumed timetable.

No established treatment should be presented as a cure for ALS. However, there are meaningful decisions to make about disease-modifying medicines, ventilation, nutrition, communication, mobility, and symptom relief. For a family considering care in China, the objective should be a comprehensive assessment and a sustainable plan that can continue after the visit. A search for a new medicine should not obscure problems that can already be addressed.

Confirm the diagnosis and document the starting point

ALS diagnosis remains fundamentally clinical. Specialists look for progressive motor impairment, appropriate neurological findings, and supporting investigations while excluding other disease processes. Electromyography can reveal evidence of motor neuron dysfunction, but an abnormal result does not independently establish ALS outside the clinical context. Muscle twitching or weakness has several possible explanations and is not itself a diagnosis.

The first assessment should also document swallowing, weight, breathing, communication, and daily activities. The ALS Functional Rating Scale-Revised helps track function, but its total does not describe every important risk. Two people with similar totals may have very different priorities: one may mainly need help with hand function, while another has symptoms suggesting inadequate ventilation during sleep. Individual items and the person's experience should guide action.

Where a previous diagnosis remains uncertain, provide the Chinese neuromuscular service with complete electrophysiology reports, relevant imaging, laboratory findings, and a chronology of symptoms. Repeating an investigation without a defined question may not resolve uncertainty. Ask what alternative explanation remains under consideration and how another test could change the clinical judgment.

Build a team around the problems ALS can create

A neurologist can coordinate diagnostic and disease-modifying decisions, while respiratory clinicians assess ventilation and secretion clearance. Dietitians and swallowing specialists address intake and safety. Rehabilitation and occupational therapy professionals can help with movement, equipment, and everyday activities. Nursing, psychological support, and palliative care can help the patient and household manage the consequences of these changes.

The 2024 European Academy of Neurology guideline emphasizes coordinated multidisciplinary care and reassessment as needs evolve. The practical issue is whether information is shared and recommendations become accessible services. A hospital containing many departments does not automatically provide a coordinated ALS pathway. Before a visit to China, clarify who brings the findings together and who will remain responsible for unresolved questions.

Follow-up should also respond to new symptoms between scheduled appointments. Increasing breathlessness, difficulty maintaining intake, or a loss of the ability to communicate may need earlier intervention. The care plan should explain how to obtain that assessment instead of assuming the next routine clinic date is always soon enough.

Discuss riluzole and edaravone on their own evidence

Riluzole is an important disease-modifying option to discuss following diagnosis. It cannot restore motor neurons that have already been lost, and its use requires review of tolerability, accompanying medicines, and relevant investigations. If swallowing tablets becomes difficult, the clinician and pharmacist should check appropriate formulations and administration. A family should not assume that crushing, substituting, or changing the route preserves safe use.

Edaravone has ALS indications in some jurisdictions, including US approval of intravenous and oral suspension formulations. The evidence needs interpretation in relation to the populations and outcomes studied; identical benefit should not be promised to every person with ALS. The 2024 EAN guideline was cautious about routine use outside trials, and the publicly reported ADORE study of a particular daily oral formulation did not meet its main functional endpoint. These findings need to be considered alongside existing approvals rather than turned into a claim that the medicine is prohibited everywhere or essential for everyone.

In China, verify the actual product, formulation, approved indication, and proposed schedule. Edaravone, edaravone combined with dexborneol, and different administration products should not be treated as interchangeable ALS therapies because their names are similar. Administration burden, possible allergy, access, and cost belong in the discussion alongside efficacy. A simple imported-versus-domestic comparison is not sufficient to choose treatment.

Tofersen offers a targeted option for a defined subgroup

Tofersen is an antisense oligonucleotide directed at SOD1 and is administered into the cerebrospinal fluid through an intrathecal procedure. China granted conditional approval in 2024 for adults with ALS associated with an SOD1 mutation. It is not a general treatment for every form of ALS. The laboratory result needs specialist interpretation, including whether the identified variant explains the clinical disease; a variant of uncertain significance should not automatically be treated as a confirmed cause.

The initial US accelerated approval relied on reduction in plasma neurofilament light, a biomarker considered reasonably likely to predict clinical benefit. The early randomized trial did not meet its primary clinical endpoint. Long-term results published in 2026 provide supportive evidence, but the extension treated all participants with tofersen and has limitations involving follow-up completion and comparisons. These findings do not justify guaranteeing restored walking or permanent arrest of progression.

Repeated lumbar puncture also creates a treatment burden. Important risks include myelitis or radiculitis, aseptic meningitis, and increased intracranial pressure with papilledema. The team should explain suitability, symptom monitoring, and how future administrations can be maintained. Even when a person is eligible for targeted treatment, nutrition, ventilation, and communication support remain part of the same care plan.

Consider genetic counseling even without a known family history

An absence of affected relatives does not exclude an identifiable genetic contribution. The 2023 consensus guideline on ALS genetic testing and counseling recommends offering testing to all people with ALS, with appropriate explanation before and after the test. This is an informed clinical discussion, not an instruction that every relative must immediately undergo the same investigations.

Possible results include a pathogenic variant, an uncertain finding, or no identifiable explanation. A negative test does not necessarily overturn the clinical diagnosis, while a positive result does not provide an exact personal rate of progression. For a consultation in China, bring the formal report, methods, and family history rather than a screenshot stating only that a genetic abnormality was detected.

The purpose of testing may include clarifying eligibility for a targeted treatment or a particular research study, as well as understanding family implications. Those purposes should be explained separately. A research opportunity linked to a gene is not the same as an approved treatment for every person with a change in that gene.

Discuss breathing before a crisis makes the decision urgent

Respiratory muscle weakness may first appear as discomfort lying flat, disrupted sleep, morning headache, daytime sleepiness, or a weak cough. It does not always begin with an obvious episode of breathlessness. Assessment combines symptoms with respiratory function and, when needed, evaluation of sleep or gas exchange. A fingertip oxygen reading alone cannot establish whether ventilation is adequate.

Where respiratory insufficiency is present, non-invasive ventilation can assist breathing, improve related symptoms, and potentially prolong survival. It does not stop the underlying disease. The interface, secretion management, training, equipment support, and assistance available at night can all affect whether the person benefits. Settings and hours of use require individual adjustment rather than copying another patient's machine.

Oxygen alone does not correct inadequate ventilation caused by weak respiratory muscles and can worsen carbon dioxide retention. Oxygen may still be needed for a separate clinical indication, but that decision requires appropriate assessment and monitoring. Cough assistance and airway clearance also deserve attention. More complex choices, including invasive ventilation, are best discussed while the person has time and support to consider the practical implications and their own preferences.

Treat nutrition as a question of safety, effort, and intake

Weight loss may reflect swallowing difficulty, prolonged meals, arm weakness, respiratory demands, appetite change, or emotional distress. Record weight and the experience of eating so the team can evaluate causes. Food consistency, seating, utensils, frequency of meals, and assistance can make a difference. A high-calorie product is not automatically suitable for every swallowing pattern and should not be presented as a universal disease-modifying treatment.

Gastrostomy should be discussed early enough to consider preferences, swallowing, weight, respiratory status, and the effort required for eating and drinking. It provides another route for nutrition and medicine; it is not a label of treatment failure. It also does not eliminate every source of aspiration. Where respiratory impairment is present, the team must coordinate ventilation support with the procedure rather than first raising the subject after severe nutritional decline.

Decisions about oral intake after a feeding tube is placed are also individual. The person should receive an explanation of what the tube is intended to achieve and which risks still need management. Practical teaching for the household and access to appropriate supplies matter as much as completing the procedure itself.

Preserve communication and participation

Difficulty speaking does not establish inability to understand. Communication support may begin with an alphabet or picture board and develop toward other tools as hand, eye, and physical abilities change. Voice banking and eye-gaze systems require assessment and practice. Discussing them before communication becomes severely restricted can give the person more choice and time to become familiar with equipment.

Rehabilitation should fit current function and fatigue. Its aims can include maintaining range of movement, reducing discomfort, and helping everyday tasks become more manageable. Exhaustion is not a useful measure of success, and intense training should not be sold as a way to reverse motor neuron loss. Braces, wheelchairs, transfer aids, and environmental changes may reduce immediate difficulties and prevent avoidable injury.

Some people with ALS also experience cognitive or behavioral changes. Problems with decision-making or accepting support should be assessed rather than automatically attributed to personality. The team may need to adapt how information is presented while continuing to involve the patient in decisions as far as possible.

Give symptoms their own treatment goals

Drooling, thick secretions, cramps, pain, constipation, poor sleep, and emotional distress can substantially affect daily life. Each deserves an assessment of causes and practical treatment options. An intervention that helps one symptom may create another burden, such as thicker secretions after measures to reduce saliva or increased sleepiness from a medicine. Review should consider those trade-offs.

Palliative care can work alongside disease-modifying treatment and ventilation. It may help with symptom relief, difficult decisions, and discussion of future needs. It should not be equated with the withdrawal of all active care. The patient's informed preferences should guide choices, and caregivers need access to support rather than being expected to manage every task indefinitely without help.

Check research claims against the current record

Relyvrio, also known as AMX0035, illustrates why older approval news needs updating. Following the negative PHOENIX phase 3 trial, the product was removed from the market, and the FDA published formal withdrawal of approval in 2025. A historical description as a newly approved medicine does not establish its status as a current treatment in 2026.

Study registration, expanded access, and orphan designation also differ from evidence that an intervention works. The EAN guideline does not support cell-based therapies as routine ALS treatment. A commercial promise to repair motor neurons should be checked against the actual human evidence, study design, and applicable regulatory status. Participation in legitimate research should not displace necessary respiratory, nutritional, or symptom care.

Make a visit to China serve a defined purpose

List what the visit is intended to resolve: diagnostic review, interpretation of a genetic finding, drug assessment, ventilation adjustment, or help with swallowing and communication. Send the relevant records, including electrophysiology, imaging, genetics, weight and respiratory trends, current medicines, and equipment use. The proposed hospital can then explain which services it can provide and what information remains necessary.

For someone relying on ventilatory support, travel planning also involves power, backup arrangements, equipment carriage, trained companionship, and access to medical help. The respiratory team and actual carrier need to assess their respective requirements. Recent deterioration in breathing, inability to maintain fluids or nutrition, or an acute infection should be addressed locally before a distant appointment determines the itinerary.

Request costs separately for assessment, medicines, procedures, devices, consumables, and caregiving. A short hospital quote cannot describe the expenditure over an entire disease course. Before departure from China, confirm which clinicians and services will continue the plan at home. Useful ALS care is measured in the ability to breathe, eat, communicate, and participate more safely each day, as well as in the specific treatments a specialist can offer.

Sources

Related guides